Dynamic 82-Rb Positron Emission Tomography (PET) for the Grading of KIDney Carcinoma

Starting soon · Phase 2

Conditions studied: Renal Cell Carcinoma

In brief

This is a pilot prospective longitudinal monocentric, non-comparative, nonrandomised, and non-controlled open study. is to test whether the intensity of 82-Rb uptake on PET acquisitions is associated to the aggressiveness of RCC on histology (ISUP grades), i.e., to successfully identify high-grade (ISUP grades 3 and 4) vs. lowgrade (ISUP grades 1 and 2) RCC.

Key facts

Study ID

NCT07346404

Run by

Assistance Publique - Hôpitaux de Paris

People needed

50

Starts

2026-01-01

Expected to finish

2028-01-01

Last updated by the study team

2026-01-16

Who can join

Age: 18 and older, up to 90. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Age ≥ 18 years old
• Signed written informed consent
• French Social Security affiliation
• Patients with high suspicion of or confirmed RCC requiring surgical resection
• Kidney tumor diameter between 2 cm and 7 cm with clear cell imaging feature (hyper vascular lesion with contrast-enhancement similar to the renal cortex on CTA)
• Willingness and ability to comply with scheduled visits, treatment plans, laboratory tests, and other study procedures

You may not qualify if…

• Pregnant or breastfeeding women
• Patient under legal protection (guardianship)
• Contraindication to the PET-CT
• Contraindication to the injection of 82-Rb
• Participation in another interventional study involving human participants or being in the exclusion period at the end of a previous study involving human participants, if applicable
• Patient on SMA (state medical aid)
• Unilateral renal agenesis
• Multicystic renal dysplasia
• Hereditary forms of RCC as VHL, MET, FH and FLCN
• Bosniak 3 cysts
• Hypovascular lesions with enhancement inferior to the renal cortex in corticomedullary-phase images on CTA
• Exclusion of clear renal cell adenocarcinoma on biopsy
• Kidney tumors with high suspicion of extra-renal extension (cT3b, cT3c, cN+ or M+).

Where it is running

• AP-HP - hôpital européen Georges-Pompidou — Paris, France
• AP-HP - hôpital européen Georges-Pompidou — Paris, France

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.